Abstract
A retrospective analysis of data from the Mayo Clinic's Tapestry trial shows that whole-exome sequencing is an effective tool to identify people with hereditary breast and ovarian cancer syndrome and Lynch syndrome. The study also revealed that nearly 40% of these people, despite their cancer risk, would not qualify for preventive screening under current National Comprehensive Cancer Network guidelines.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
